Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

ALZAMEND NEURO, INC. (ALZN) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

ALZAMEND NEURO, INC. (ALZN), most recent 12 months reported: net loss $8.77M. Latest balance sheet on file: liquid cash $7.59M. From SEC filings. Others in Pharmaceutical Preparations: AEON Biopharma, Inc. · Akari Therapeutics, Plc · ALDEYRA THERAPEUTICS, INC. · ALX ONCOLOGY HOLDINGS INC · Amylyx Pharmaceuticals, Inc. · ANEBULO PHARMACEUTICALS, INC. · ANIXA BIOSCIENCES, INC. · ANNEXON, INC.

Stock screener

Watchlist